30.28USD+3.98%Mkt Cap: 566.45M USDP/E: —Last update: 2026-05-26
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe tech…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap566.45M USD
Enterprise Value305.89M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-74.15M USD
Revenue/Share—
Last Price30.28 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees60
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.09
PEG—
EV/EBITDA-3.33
EV/Revenue—
P/S—
P/B2.13
EPS (TTM)-4.46
EPS (Forward)-4.68
52W Range
14.3973% of range36.03
52W High36.03 USD
52W Low14.39 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-29.50%
ROA-28.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.08M USD
CapEx (TTM)208.00K USD
FCF Margin—
FCF Yield-7.89%
Net Debt-232.26M USD
Net Debt/EBITDA2.53
Balance Sheet
Debt/Equity0.01
Current Ratio18.51
Quick Ratio18.28
Book Value/Sh13.41 USD
Cash/Share12.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJun 21, 2024
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)77.89 USD
Target Range60.00 USD – 101.00 USD
# Analysts9
Ownership
Shares Out.18.87M
Float11.23M
Insiders39.34%
Institutions74.13%
Short Interest
Short Ratio12.0d
Short % Float27.36%
Short % Out.13.02%
Shares Short2.45M
Short (prev mo.)2.41M
Technical
SMA 5029.52 (+2.6%)
SMA 20022.52 (+34.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)231.26K
Avg Vol (10d)285.18K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—